BRPI0510942A - combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b - Google Patents

combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b

Info

Publication number
BRPI0510942A
BRPI0510942A BRPI0510942-6A BRPI0510942A BRPI0510942A BR PI0510942 A BRPI0510942 A BR PI0510942A BR PI0510942 A BRPI0510942 A BR PI0510942A BR PI0510942 A BRPI0510942 A BR PI0510942A
Authority
BR
Brazil
Prior art keywords
disorder
pharmaceutically acceptable
disorders
syndrome
sym
Prior art date
Application number
BRPI0510942-6A
Other languages
English (en)
Inventor
Michael Aaron Brodney
Christopher John Helal
Brian Scott Bronk
Spiros Liras
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0510942A publication Critical patent/BRPI0510942A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMBINAçãO DE ANTIPSICóTICOS ATìPICOS E ANTAGONISTAS DO RECPTOR 5- HT<sym> A presente invenção diz respeito a uma composição farmacêutica para tratar, por exemplo, uma desordem ou condição selecionada do grupo que consiste em hipertensão, depressão desordem da anisedade generalizda, fobia, desordem do estresse pós-traumático, desorem da personalidade evitativa, disfunção sexual, desordens da alimentação, obesidade, dependências químicas, dor de cabeça em salvas, enxaqueca, dor, doença de alzheimer, desordem compusiva obsessiva, desordem do pânico, desordens da memória, doenças de parkinson, desordens endócrinas, ataxia cerebelar, desordens do trato gastrintestinal, sintomas negativos de esquizofrenia, síndrome pré mestrual, síndrome de fibromialgia, incontinência do estresse, síndrome de Tourette, tricotolomania, cleptomania, impotênica masculina, câncer, hemicrânia paroxística crónica e dor de cabeça em um mamífero, preferivelmente um humano,compreendendo (i) um antipsicótico atípico ou um sal farmaceuticamente aceitável destes, (ii) um antagonista do recptor 5-HT <sym> ou um sal farmaceuticamente aceitavel destes, em que o antagonista do recptor 5-HT <sym> é selecionado do grupo que consiste em (A) um composto da fórmula I da maneira descrita na especificação e (B) um composto da formula II a maneira descrita na especificação, e opcionalmente (iii) um carreador farmaceuticamente aceitável..
BRPI0510942-6A 2004-05-11 2005-04-29 combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b BRPI0510942A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56992704P 2004-05-11 2004-05-11
PCT/IB2005/001195 WO2005107808A2 (en) 2004-05-11 2005-04-29 Combination of atypical antipsychotics and 5-ht1b receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0510942A true BRPI0510942A (pt) 2007-07-17

Family

ID=35094168

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510942-6A BRPI0510942A (pt) 2004-05-11 2005-04-29 combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b

Country Status (7)

Country Link
US (1) US20050256112A1 (pt)
EP (1) EP1753460A2 (pt)
JP (1) JP2007537232A (pt)
BR (1) BRPI0510942A (pt)
CA (1) CA2565996A1 (pt)
MX (1) MXPA06013163A (pt)
WO (1) WO2005107808A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8349288B2 (en) * 2006-12-06 2013-01-08 The Regents Of The University Of California Process for enhancing the operability of hot gas cleanup for the production of synthesis gas from steam-hydrogasification producer gas
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
MX2007004485A (es) * 2004-10-15 2007-06-13 Organon Nv Tratamiento de desordenes bipolares y sintomas asociados.
US7754491B2 (en) * 2005-12-09 2010-07-13 The Regents Of The University Of Calif. Sensor for measuring syngas ratios under high temperature and pressure conditions
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
US7645750B2 (en) * 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
EP2170399A1 (en) * 2007-06-05 2010-04-07 Synthon B.V. Intranasal administration of asenapine and pharmaceutical compositions therefor
US8420624B2 (en) * 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
WO2011109367A2 (en) * 2010-03-02 2011-09-09 Royster Jr George E Methods and compositions for treating or preventing symptoms of hormonal variations
US8461102B2 (en) 2010-03-02 2013-06-11 George E. Royster, JR. Methods and compositions for treating and preventing symptoms of hormonal variations
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神***病を処置するための方法および組成物
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
AU2017384526B2 (en) 2016-12-20 2023-11-02 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
JP2020525545A (ja) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
US11376337B2 (en) 2017-11-02 2022-07-05 California Institute Of Technology Expression of neuropeptides
EP3704271A4 (en) * 2017-11-02 2021-09-08 California Institute of Technology NEUROKININ ANTAGONISTS AND RELATED USES
CA3101420A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5238945A (en) * 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
EP0746317B1 (en) * 1994-03-02 1998-06-10 Akzo Nobel N.V. Sublingual or buccal pharmaceutical composition
SK131498A3 (en) * 1996-03-29 2000-09-12 Pfizer BENZYL(IDENE)-LACTAM DERIVATIVES, THEIR PREPARATION AND THEIR USEì (54) AS SELECTIVE (ANT)AGONISTS OF 5-HT1A- AND/OR 5-HT1D
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
PT810220E (pt) * 1996-05-28 2002-04-29 Pfizer Derivados de arilacrilamida como agonistas ou antigonistas de 5ht1
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
PT952154E (pt) * 1998-04-16 2004-12-31 Pfizer Prod Inc N-acil- e n-aroil-aralquilamidas
US6387904B2 (en) * 1998-05-18 2002-05-14 Pfizer Inc Method of treating glaucoma and ischemic retinopathy
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1451166B1 (en) * 2001-12-07 2005-08-10 Pfizer Products Inc. Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
WO2005107808A2 (en) 2005-11-17
EP1753460A2 (en) 2007-02-21
US20050256112A1 (en) 2005-11-17
MXPA06013163A (es) 2007-02-13
JP2007537232A (ja) 2007-12-20
WO2005107808A3 (en) 2006-05-11
CA2565996A1 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
BRPI0510942A (pt) combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
BRPI0507190A (pt) combinação de moduladores do ácido gama-aminobutìrico e antagonistas de 5-ht1b receptores
JP5572157B2 (ja) Ｎｏｓ阻害活性を有するベンゾオキサジン類、ベンゾチアジン類、および関係化合物
EA200600049A1 (ru) Способы получения 3 - бензазепинов
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
NO20065814L (no) Thiendopyridinon forbindelser og fremgangsmater for behandling
EA200701357A1 (ru) Композиции и способы применения модулятора рецептора 5ht
EA200601802A1 (ru) Производные морфолина
CA2705833A1 (en) 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
BRPI0513433A (pt) derivados de hidantoìna para o tratamento de distúrbios inflamatórios
UY30414A1 (es) Metano sulfonatos, propano-1-sulfonatos y ciclopropan sulfonatos sustituidos con [2,3,4,8-tetrahidroimidazo-[1,5-al-pirimidin-8-il]-fenilo, composiciones farmacéuticas conteniéndolos y aplicaciones.
ATE466858T1 (de) 3-arylisoxazol-4-carbonylbenzofuranderivative
ATE438632T1 (de) Aryl-4-ethinylisoxazolderivate
TW200621245A (en) Thienopyridinone compounds and methods of treatment
EA200801302A1 (ru) Композиции и способы лечения нарушений цнс
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
BRPI0613491A2 (pt) antagonistas de piperazina-piperidina e agonistas do receptor de 5-ht1a
BR0317422A (pt) Compostos de n-(indoletil) cicloamina
EA200800421A1 (ru) Соединения
BRPI0413584A (pt) composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de doenças e para tratamento de um distúrbio no sistema nervoso central
ATE495159T1 (de) Diaminocyclohexan- und diaminocyclopentanderivate
BRPI0816571A2 (pt) &#34;composto, processo para preparação do composto, composição farmacêutica, agente e método para o tratamento de uma doença ou uma desordem do sistema nervoso central relacionada à ou afetada pelo recptor 5-ht6&#34;
BRPI0511419A (pt) derivado de lactama de pirazinilmetila

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6 ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6 NA RPI 2099 DE 29/03/2011.